Starting in September 2026, it is mandatory for organizations to submit full briefing documents along with their scientific advice requests. This introduces an earlier checkpoint for preparing safety-related materials such as RMPs and PASS protocols.
This change necessitates that pharmacovigilance teams intensify their efforts to finalize safety documentation much earlier in the product development lifecycle, thereby increasing coordination between regulatory and pharmacovigilance teams.
PV teams must prepare and finalize safety-related briefing materials, including risk management plans and protocols, for initial submission by September 2026.
Regulatory Intelligence Lead
Review before 2026-09-01.
Mandatory submission of the full briefing document(s) at the point of request for scientific advice; implementation effective from September 2026.
This change requires PV teams to finalize safety-related briefing materials—including RMPs, PASS protocols, and risk management strategies—much earlier in the development lifecycle. Regulatory and PV coordination must be intensified to ensure all safety documentation is ready for the initial submission.
Increased preparation time and documentation requirements for organizations seeking advice.
Organizations must submit a briefing document at the point of submission.
PV teams must prepare and finalize safety-related briefing materials, including risk management plans and protocols, for initial submission by September 2026.
The MHRA has updated its procedural guidance on the submission of briefing materials for scientific advice requests. This change mandates that organizations must provide complete briefing documents at the time of submission, significantly earlier in the process than previously required.
What changed: Starting in September 2026, it is mandatory for organizations to submit full briefing documents along with their scientific advice requests. This introduces an earlier checkpoint for preparing safety-related materials such as RMPs and PASS protocols.
Why it matters: This change necessitates that pharmacovigilance teams intensify their efforts to finalize safety documentation much earlier in the product development lifecycle, thereby increasing coordination between regulatory and pharmacovigilance teams.
Practical implication: PV teams must prepare and finalize safety-related briefing materials, including risk management plans and protocols, for initial submission by September 2026.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
